Modest Response Rates in Endometrial Cancers

Vicky Makker, MD

Vicky Makker, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses 2 agents, lenvatinib and pembrolizumab, in patients with endometrial cancers.

Vicky Makker, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses 2 agents, lenvatinib (Lenvima) and pembrolizumab (Keytruda), in patients with endometrial cancers.

While lenvatinib has previously been approved for the treatment of radioactive iodine—refractory differentiated thyroid cancer, as well as in advanced renal cell carcinoma in combination with everolimus (Afinitor), this agent has shown a modest response rate of 14% in patients with heavily pretreated endometrial cancer.